US study seeking to confirm strong efficacy data reported in RED DESERT and SAHARA Initial data expected in Q4 2023 Ghent, Belgium – 10 July 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces...Read More